Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs.
Erika P BergerChad M JohannesAlbert E JergensKarin AllenspachBarbara E PowersYingzhou DuJonathan P MochelLeslie E FoxMargaret L MusserPublished in: Journal of veterinary internal medicine (2018)
Biological activity of toceranib is evident in dogs with gross disease. Metastasis of GIST at diagnosis, as well as high tumor mitotic index, was associated with shorter PFI in toceranib-treated dogs. Larger studies are needed to define postsurgical risk and refine the use of toceranib in dogs with gross and microscopic GIST.